Tilray Brands trades on the Nasdaq under the ticker TLRY, and while its fundamentals have improved, one critical external factor still drives its outlook.
The Canada-based cannabis company has made progress carving a path toward steady profits while also strengthening its balance sheet.
When Tilray reported earnings on April 1 for the third fiscal quarter of 2026, ending February 28, it had notable results to highlight.
Overall net revenue and gross profit growth came in relatively modest, at 11% and 6% respectively, but the international cannabis segment stood out sharply.
That segment, consisting largely of exports of medical-grade cannabis to Europe, reported 73% year-over-year sales growth last quarter.
The company also reported a 19% year-over-year improvement in adjusted EBITDA, rising from $9 million to $10.7 million, alongside a net loss of $25.2 million.
Management reiterated guidance for the fiscal year ending June 30, forecasting an adjusted EBITDA range of $62 million to $72 million.
Despite these improvements, the market values Tilray at around $630 million, a figure tied largely to the potential for the company to enter the U.S. market.
The possible reclassification of marijuana from a Schedule I drug to Schedule III in the U.S. remains the central catalyst, but the timeline for legalization remains cloudy.
Tilray shares would likely rally temporarily on any rescheduling or legalization news, but the path forward remains uncertain and dependent on federal regulatory action.
Other marijuana stocks, including companies that operate at the state level in the U.S., carry catalysts beyond rescheduling and may offer greater and clearer upside at this time.
Improved fundamentals alone are unlikely to return Tilray to the elevated prices it has previously reached without meaningful progress on U.S. cannabis policy reform.
